DR REDDYS LABORATORIES LTD(RDY)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
RDY Stock Analysis & AI Quality Score
AI stock analysis and institutional research for DR REDDYS LABORATORIES LTD (RDY), a Healthcare sector company. RDY is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (FY 2025), DR REDDYS LABORATORIES LTD reports quarterly revenue of $3.8B, net income of $671.0M. Top institutional holders of RDY by reported 13-F value include Robeco Institutional Asset Management B.V., BlackRock,, ROYAL BANK OF CANADA, based on the most recent SEC filings. RDY trades on the NYSE exchange and files with the SEC under CIK 1135951. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RDY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DR REDDYS LABORATORIES LTD directly from SEC EDGAR.
Revenue
FY 2025
$3.8B
Net Income
FY 2025
$671.0M
AI Insight: RDY Financial Trends
Insufficient data to assess financial trends — all metrics are missing across the 8-quarter period.
• No financial data available from Q1 2018 through Q1 2025.
⚠ Data gap prevents analysis of revenue growth, profitability, cash generation, and leverage trends.
AI Insight: RDY Ratio Trends
Insufficient data to assess RDY's financial trend — all ratio fields are empty across the entire period.
• No operational margin, profitability, or return metrics available for analysis from Q1 2018 through Q1 2025.
⚠ Data gap prevents monitoring of leverage (D/E), ROIC trends, and margin expansion — critical for pharma competitive health assessment.
Get alerted when RDY's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for DR REDDYS LABORATORIES LTD including:
Top Institutional Holders of RDY
Robeco Institutional Asset Management B.V.
$237.9M17,177,882 shBlackRock, Inc.
$160.5M11,587,127 shROYAL BANK OF CANADA
$138.3M9,984,082 shMORGAN STANLEY
$129.8M9,371,594 shAikya Investment Management Ltd
$110.8M7,999,796 shRENAISSANCE TECHNOLOGIES LLC
$108.9M7,859,728 shDIMENSIONAL FUND ADVISORS LP
$73.7M5,323,248 shSTATE STREET CORP
$55.8M4,026,207 shBNP PARIBAS FINANCIAL MARKETS
$44.1M3,183,971 shVANGUARD CAPITAL MANAGEMENT LLC
$42.9M3,100,911 sh
| Fund | Value | Shares |
|---|---|---|
| Robeco Institutional Asset Management B.V. | $237.9M | 17,177,882 |
| BlackRock, Inc. | $160.5M | 11,587,127 |
| ROYAL BANK OF CANADA | $138.3M | 9,984,082 |
| MORGAN STANLEY | $129.8M | 9,371,594 |
| Aikya Investment Management Ltd | $110.8M | 7,999,796 |
| RENAISSANCE TECHNOLOGIES LLC | $108.9M | 7,859,728 |
| DIMENSIONAL FUND ADVISORS LP | $73.7M | 5,323,248 |
| STATE STREET CORP | $55.8M | 4,026,207 |
| BNP PARIBAS FINANCIAL MARKETS | $44.1M | 3,183,971 |
| VANGUARD CAPITAL MANAGEMENT LLC | $42.9M | 3,100,911 |
More Healthcare Companies
View all Healthcare →Put RDY on your watchlist
Track score changes the day DR REDDYS LABORATORIES LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RDY a good stock to buy?
13F Pro's AI-powered analysis of DR REDDYS LABORATORIES LTD (RDY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RDY are available on the RDY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own RDY?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RDY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DR REDDYS LABORATORIES LTD's investment landscape.